产品简要
公司名称 :
赛默飞世尔
其他品牌 :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
产品类型 :
抗体
产品名称 :
c-Abl Monoclonal Antibody (8E9)
目录 :
MA5-14398
规格 :
500微升
价格 :
美国446.00
克隆性 :
单克隆
宿主 :
小鼠
共轭标签 :
未共轭
克隆名称 :
8E9
反应物种 :
人类, 小鼠
应用 :
免疫印迹, 免疫组化, 免疫细胞化学, 免疫沉淀, 免疫组化-石蜡切片
更多信息或购买 :
文章摘录数: 7
出版应用/物种/样本/稀释参考文献
  • 免疫组化; 人类
Noguera I, Sun C, Broaddus R, Branham D, Levenback C, Ramirez P, et al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol. 2012;125:640-5 pubmed 出版商
  • 免疫沉淀; 小鼠
  • 免疫细胞化学; 小鼠
  • 免疫印迹; 小鼠
Baker M, Hetherington L, Curry B, Aitken R. Phosphorylation and consequent stimulation of the tyrosine kinase c-Abl by PKA in mouse spermatozoa; its implications during capacitation. Dev Biol. 2009;333:57-66 pubmed 出版商
  • 免疫细胞化学; 小鼠
Preyer M, Shu C, Wang J. Delayed activation of Bax by DNA damage in embryonic stem cells with knock-in mutations of the Abl nuclear localization signals. Cell Death Differ. 2007;14:1139-48 pubmed
  • 免疫组化; 人类
Coleman R, Broaddus R, Bodurka D, Wolf J, Burke T, Kavanagh J, et al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol. 2006;101:126-31 pubmed
Slomovitz B, Broaddus R, Schmandt R, Wu W, Oh J, Ramondetta L, et al. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. Gynecol Oncol. 2004;95:32-6 pubmed
Woodring P, Meisenhelder J, Johnson S, Zhou G, Field J, Shah K, et al. c-Abl phosphorylates Dok1 to promote filopodia during cell spreading. J Cell Biol. 2004;165:493-503 pubmed
Schmandt R, Broaddus R, Lu K, Shvartsman H, Thornton A, Malpica A, et al. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer. 2003;98:758-64 pubmed
图像
图像 1 :
赛默飞世尔 MA5-14398 图像 1
图像 2 :
赛默飞世尔 MA5-14398 图像 2
产品信息
产品类型 :
抗体
产品名称 :
c-Abl Monoclonal Antibody (8E9)
目录# :
MA5-14398
规格 :
500微升
价格 :
美国446.00
克隆性 :
单克隆
纯度 :
蛋白质G
宿主 :
小鼠
反应物种 :
人类
应用 :
Immunocytochemistry: 1:10-1:100, Immunohistochemistry (Paraffin): 1:20, Immunoprecipitation: 2 µg/mg protein lysate, Western Blot: 1:50
物种 :
人类
克隆 :
8E9
抗体亚型 :
IgG1
储存 :
4° C
描述 :
c-Abl (Abelson murine leukemia viral oncogene homolog 1, ABL1) is a 140 kDa proto-oncogene member of the Src family of non-receptor tyrosine kinases. c-Abl has been implicated in processes of cell differentiation, cell division, cell adhesion, and stress response. Activity of c-Abl protein is negatively regulated by its SH3 domain, and deletion of the SH3 domain turns c-Abl into an oncogene. The t(9;22) translocation results in the head-to-tail fusion of the BCR and c-Abl genes present in many cases of chronic myelogeneous leukemia. The DNA-binding activity of the ubiquitously expressed ABL1 tyrosine kinase is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function for c-Abl. In chronic myelogenous leukemia and a subset of acute lymphoblastic leukemias, the c-Abl proto oncogene undergoes a (9;22) chromosomal translocation producing a novel rearranged chromosome (the Philadelphia chromosome) As the result of the fusion of c-Abl sequences from chromosome 9 to the Bcr gene on chromosome 22. The molecular consequence of this translocation is the generation of a chimeric Bcr/Abl mRNA encoding activated Abl protein tyrosine kinase. The c-Abl oncogene was initially identified as the viral transforming gene of Abelson murine leukemia virus (A-MuLV). The major translational product of c-Abl has been identified as a protein with tyrosine kinase activity and an SH2 domain. The c-Abl oncogene is implicated in several human leukemias including 90-95% of chronic myelocytic leukemia (CML), 20-25% of adult acute lymphoblastic leukemia (ALL) and 2-5% of pediatric ALL. c-Abl localizes to dynamic actin structures, and phosphorylates CRK and CRKL, DOK1, and other proteins controlling cytoskeleton dynamics. c-ABL potentially regulates DNA repair by activating the proapoptotic pathway when the DNA damage is too severe to be repaired.
免疫原 :
Recombinant Abl protein
格式 :
液体
应用w/稀释 :
Immunocytochemistry: 1:10-1:100, Immunohistochemistry (Paraffin): 1:20, Immunoprecipitation: 2 µg/mg protein lysate, Western Blot: 1:50
别名 :
Abelson murine leukemia oncogene; Abelson murine leukemia viral (v-abl) oncogene homolog 1; abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine-protein kinase 1; Abl; Abl 1 antib; ABL proto-oncogene 1, non-receptor tyrosine kinase; Abl1; ABL2; ABLL; AI325092; ARG; B30; bcr/abl; bcr/c-abl oncogene protein; c-ABL; c-abl oncogene 1, non-receptor tyrosine kinase; c-abl oncogene 1, receptor tyrosine kinase; c-ABL1; E430008G22Rik; JTK7; p150; Proto-oncogene c-Abl; proto-oncogene tyrosine-protein kinase ABL1; RP11-83J21.1; Tyrosine kinase ARG; tyrosine-protein kinase ABL1; v-abl; v-abl Abelson murine leukemia oncogene 1; v-abl Abelson murine leukemia viral oncogene 1; v-abl Abelson murine leukemia viral oncogene homolog 1
更多信息或购买 :
公司信息
赛默飞世尔
上海浦东新金桥路27号7号楼
analyze.cn@thermofisher.com
http://www.thermo.com.cn
1084193588
公司总部: 美国